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Abstract
Vitamin K carboxylase (VKC) is believed to convert vitamin K, in the vitamin K cycle, to an
alkoxide-epoxide form which then reacts with CO2 and glutamate to generate γ-carboxyglutamic
acid (Gla). Subsequently, vitamin K epoxide reductase (VKOR) is thought to convert the
alkoxide-epoxide to a hydroquinone form. By recycling vitamin K, the two integral-membrane
proteins, VKC and VKOR, maintain vitamin K levels and sustain the blood coagulation cascade.
Unfortunately, NMR or X-ray crystal structures of the two proteins have not been characterized.
Thus, our understanding of the vitamin K cycle is only partial at the molecular level. In this study,
based on prior biochemical experiments on VKC and VKOR, we propose a hetero-dimeric form of
VKC and VKOR that may explain the efficient oxidation and reduction of vitamin K during the
vitamin K cycle.
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1. Introduction
Vitamin K plays a key role in the blood coagulation cascade [1,2]. Through the vitamin K
cycle, vitamin K helps to generate γ-carboxyglutamic acid (Gla) from glutamic acid (Glu).
Gla enables several blood coagulation proteins, (factor II, factor VII, factor IX, factor X,
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protein C and protein S, …), to establish a fold necessary for anchoring to anionic lipid
membranes in the presence of Ca2+ and thereby trigger and propagate the blood coagulation
cascade [2–5].
At least, two trans-membrane (TM) proteins, vitamin K carboxylase (VKC, also referred to
as GGCX) and vitamin K epoxide reductase (VKOR, also referred to as VKORC1), are
involved in the vitamin K cycle at the endoplasmic reticulum (ER). The human sequences of
VKC with 758 residues [6–8] and VKOR with 163 residues [9,10] have been identified.
VKC has been suggested by Dowd to catalyze the formation of an activated form of vitamin
K from the hydroquinone [11–13]. This alkoxide-epoxide form then abstracts a proton from
glutamic acid (Glu) so that the resulting carbanion may react with CO2 to generate Gla. This
is a 4 electron process. VKOR, on the other hand, converts the alkoxide-epoxide back to the
quinone form (a 2 electron process), followed by reduction to the subsequent hydroquinone
form (a fully reduced form) by VKOR (a 2 electron process) to complete the cycle. (See
Supporting Materials) The last step remains controversial [14]. The mechanism for the
reduction of the alkoxide-epoxide form to the quinone form has been studied both
experimentally and theoretically [15,16]. The essence of the reduction mechanism involves a
sequential participation of two cysteine residues. Thus, through a series of the oxidation and
reduction processes, vitamin K is presumably recycled as shown in Fig.1.
Even though sequences and several functions of VKC and VKOR are known and the
putative mechanisms of oxidation and reduction have been proposed, the structures and
relative orientations of the two TM proteins have not been characterized. Then, several
important questions arise: How does the largely hydrophobic vitamin K interact with the two
TM proteins? How do these two TM proteins bind to the substrate, a vitamin K-dependent
protein (VKD), both modifying vitamin K, to generate Gla from Glu on a specific domain?
How can these two TM proteins control the vitamin K cycle efficiently within the bounds of
a membrane?
Vitamin K is composed of a long hydrophobic chain and naphthoquinone unit. The human
pool is very small (~100 μg) and the turnover rate is rapid (~1.5 days) [17], thus we can
surmise that its use must be quite efficient. We can conjecture that once the lipophilic tail of
a vitamin K is anchored in membrane, vitamin K would be restricted to lateral diffusion in
the membrane. If VKC and VKOR were randomly separated, vitamin K and its
intermediates would have to diffuse between geometrically separated active sites, (possibly
involving Lys218 for VKC and Cys132, Cys135 for VKOR) to effect the oxidation/
reduction process. Instead, if we envision that VKC and VKOR are co-localized as a hetero-
dimer in the ER membrane, the inefficiency of diffusion of the vitamin K intermediates is
minimized. We therefore propose the co-localization of VKC and VKOR to account for the
observed efficient vitamin K cycle. A schematic co-localization model was previously
proposed to account for the possible interaction of VKC/VKOR with calumenin in the ER
lumen [18–20].
The formation of a hetero-dimer protein complex within membrane does exist in nature. For
instance, a hetero-dimeric form of two TM proteins has been found in the maltose transport
system. MalF and MalG, composed of eight TM helices and six TM helices respectively,
form a hetero-dimer: two crescent shaped TM domains face each other in a concave manner
and enclose a maltose molecule [21,22]. Similarly, a TM complex involving 4 subunits has
been characterized for the ubiquinol oxidase system [23]. For a deeper understanding of the
vitamin K cycle, clearly more accurate information about the 3D structures of VKC and
VKOR will be ultimately required. Despite the absence of structural information of VKC
and VKOR, however, there have been significant biochemical experiments on these two
proteins. In this study, based on these prior biochemical experiments, computer-aided
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prediction of TM units, and quantum chemical study, we have built a rational model of the
putative hetero-dimeric form of VKC and VKOR. We find that the hetero-dimer of VKC
and VKOR is compatible with the intermediate vitamin K structures proposed in the Dowd
mechanism. The model is also helpful in accounting for the observed non-competitive
inhibition of VKOR by warfarin [24].
2. Methods
All the structures in Fig.1 were fully geometry optimized using Gaussian03 [25,26] with the
method/basis of B3lyp/6-31+g(d,p) in gas-phase. In the preparation of the vitamin K and its
derivatives, the methyl group (R1) and the long hydrophobic side chain (R2) after the first
side-chain double bond were replaced by hydrogens [27]. Since the structure of VKC and
VKOR have not been characterized, we used one of the TM helix units of sensory rhodopsin
II (PDB : 1JGJ) [28] as a template in building our TM model. Since the sequences of VKC
and VKOR that span the membrane range from 20 to 23 residues in our predicted model, the
size of the rhodopsin template can be used for both VKC and VKOR. For the eight TM helix
units (minimalist model) in our model, we used the rhodopsin TM helix unit with 25
residues (VGLTTLFWLGAIGMLVGTLAFAWAG). The lengths for TM helices in
rhodopsin with more than 20 residues is measured to be 32.7 Å for Leu21-Thr43 (Cα-Cα; 22
residues) and 35.4 Å for Arg100-Ala124 (Cα-Cα; 24 residues) respectively. Thus, a
reasonable length distribution for TM helices of VKC and VKOR in our predicted model is
taken to be approximately 30 Å ~ 35 Å, consistent with the single rhodopsin helix we chose
as a reference. In fact, recent molecular dynamics simulations by our group (unpublished) on
VKOR models inserted in a model lipid membrane of this size (i.e. bilayer length : 38 Å ~
40 Å) appear to be relatively stable for approximately 13ns. The radius (r) of TM helix
backbone in our model was set to 3.5 Å. Our hetero-dimer model was built with VMD 1.8.7
[29].
3. Results and discussion
3.1 Location of putative active sites of VKC and VKOR
Of special significance, Lys218 has been implicated in playing a critical role in the
deprotonation of the hydroquinone form of vitamin K and the subsequent initiation of the
carboxylation reaction of VKC on the lumenal side of ER membrane [30]. Likewise,
biochemical mutation experiments have revealed that Cys132 and Cys135 in the CXXC
motif of VKOR are strong candidates for the redox center inside the membrane [31]. These
putative active site residues of VKC (Lys218) and VKOR (Cys132, Cys135) therefore play
a critical role in determining the relative position and orientation of vitamin K with respect
to the two co-localized TM proteins. To locate the putative active sites of VKC and VKOR
with respect to the ER membrane, we employed TM helix prediction programs for VKC and
VKOR.
Among the various TM protein prediction programs available, we employed the Philius
Transmembrane Prediction program [32], which is based on dynamic Bayesian network
methodology and the consensus program TOPCONS [33] to predict topologies of TM
helices of the two TM proteins. TOPCONS, in fact, uses a number of prediction programs,
(SCAMPI-seq, SCAMPI-msa, PRODIV, PRO, and OCTOPUS), to produce a consensus
result and thereby improve a reliability of prediction ability. To test the prediction reliability,
we applied both methods to the case of the bacterial VKOR-like system, the structure of
which was recently determined [34]. Both methods, in fact, predict a similar result, 5 TM
helices, from the sequence information, a result consistent with the X-ray crystal structure of
the bacterial VKOR-like protein. (see Supporting Material)
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3.2 Topology of VKC based on prediction of TM helix units
For VKC (GenBankTM accession number ACF70731.1, 758 residues), both of the prediction
methods show somewhat divergent features for the TM topology (Fig.2.A). The prior
biochemical experimental observation that N-terminus is located at the cytoplasm of the ER
(inside) [6] and the C-terminus at the lumen of the ER (outside) [6] requires an odd number
of helices in the VKC topology. These experiments were based on insertion of fragments of
the VKC sequence predicted to possibly contain TM domains. The Philius Transmembrane
Prediction program predicts 5 TM helices, while TOPCONS predicts 7 TM helices.
However, experiments have supported a 5 TM helix model for VKC topology [6,35]. Thus,
we tentatively adopt 5 TM helices for VKC. In building the model of VKC, one important
structural data point for VKC was considered. According to experiment [35], a disulfide
bond between Cys99 and Cys450 exists in the lumen of the ER. This disulfide bond could
help to define and stabilize the 3-dimensional arrangement of the TM helix units of VKC
[36]. The Philius Transmembrane Prediction program was unable to accommodate the
existence of the disulfide bond in the lumen [36] as it predicts the location of the two
cysteines on the opposite sides of the ER membrane. For compatibility with the experiment
on the disulfide bond [35,36], we choose the result of TOPCONS and set the residues of the
first TM helix unit to be 62–82 in our model as shown Fig.2A. This, along with the N
terminus, places Cys99 in the lumen. Subsequently, the second and third TM helix units in
our model were chosen according to the prediction result by TOPCONS since they were in
agreement with the experiment [6]. A most important factor in choosing the fourth and fifth
TM units in our model is the location of the putative catalytic base, Lys218. According to a
K218A mutation experiment [30], the results of which strongly suggest that Lys218 is
involved in the deprotonation of vitamin K, Lys218 is located on the lumenal side of the ER
membrane, consistent with earlier experiment [6]. Considering that the precursor VKD
proteins to be post-translationally modified, and the Glu-interacting part of VKC must be
located in the lumen [37,38], the surface of the membrane on the lumenal side is the proper
location for Lys218 to be in contact with vitamin K. This is a key hypothesis. The prediction
results of TOPCONS satisfy the requirement for the lumenal location of Lys218. For that
reason, we have set the fourth and fifth TM helix units as residues 154–176 and 197–217,
respectively. The location of Lys218, near the lumen surface of membrane, is consistent
with both prediction programs. Thus, in our minimalist model, the N terminus of VKC is
located in the cytoplasm to span the membrane with 5 TM helices, ending with the C
terminus located in the lumen of the ER. It is not ruled out that there are two additional TM
domains beyond residue 217, as suggested in Ref. [6]. TOPCONS predicts two more TM
helices 252–272 and 293–313. Philius predicts TM domains at 253–272 and 283–305. The
prediction for the sixth TM helix (252–272) in VKC by TOPCONS and a TM domain there
by Philius gives a possible concurrence. If we include the TM helix (253–272) in building
our VKC model, it is also required to add one more TM helix so that the required odd
number (7 TM helices) is preserved. As a candidate for the seventh TM helix, we would
chose 293–313. As shown in Fig.2, that TM helix supported by the experiment [6] is also
predicted by TOPCONS. Thus, we could build an extended 7 TM helix model for VKC by
adding two more TM helix (252–272, 293–313). Basically, this extended model would
preserve the termini topology of 5TM VKC model. We will proceed, however, using the
minimum number of TM domains that appear to define the active site since we have no
mutational data as yet that substantiates a 7 TM choice. The disulfide bond (Cys99-Cys450)
would be located on the lumenal side in either a 5 or 7 TM model.
3.3 Topology of VKOR based on prediction of TM helix units
For VKOR (163 residues), on the other hand, both programs give a consistent picture of the
VKOR topology: 3 TM helices as shown in Fig.2.B. In addition, the two prediction results
are consistent with experiment [39]. Unlike the complications of VKC, the active site
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participants of VKOR, Cys132 and Cys135, are predicted to be located inside the
membrane. The N-terminus of VKOR starts from the lumen of the ER to span the membrane
with 3 TM helices. Therefore, the C-terminus becomes located in the cytoplasm of the ER
[39]. The topologies of VKC and VKOR by experiments and computer prediction are
summarized in Fig.2. We assigned numbers (1–5) to each TM helix units of VKC. To avoid
confusion, we assigned letters (A–C) to each TM unit of VKOR: the first helix unit A (9–
29), the second helix unit B (104–124), and the third C (127–150). For the hetero-dimer with
8 TM helices (5⊕3: 5 TM helices from VKC and 3 TM helices from VKOR), and using 7Å
as the estimated diameter for each helix backbone, we estimated the diameter of the
“idealized pocket” is 12Å and the subtended area 110Å2. (Fig.3) The “pocket” in our hetero-
dimer model must be able to accommodate the intermediate structures of the vitamin K and
the parts of peptide chain of the VKD protein that is to be carboxylated.
3.4 Quantum chemical study
According to the Dowd mechanism for the carboxylation of Glu, one of the intermediates of
vitamin K is a glutamate carbanion, a key element in the “base amplification” process
[11,27]. The quantum mechanically energy-optimized model structure for the transition state
involving the carbanion is shown in Fig.4. This transition state is composed of three
different moieties: vitamin K alkoxide-epoxide, a water molecule, and idealized glutamic
acid (propionic acid). In Fig.4, we also indicated a putative backbone chain as a thick arrow.
We surmise that the oxygen (oxy-3 denoted in Fig.1) of the vitamin K alkoxide-epoxide
(geometry-optimized with the method/basis B3lyp/6-31+g(d,p)) will be located near Lys218
(VKC) to initiate the vitamin K cycle. Then, as a next step, we further surmise that another
oxygen, oxy-2 denoted in Fig.1, will be located near the putative active site, Cys132 and
Cys135, of VKOR for reduction of alkoxide-epoxide form to the quinone form during the
vitamin K cycle. The near contact of the epoxide oxygen (oxy-2) with the two cysteines
leaves the naphthoquinone unit of the vitamin K alkoxide-epoxide tilted in a clockwise
manner as shown in Fig.3. The two constraints -(oxy-3:Lys218 and oxy-2:Cys132, Cys135)-
require that the naphthoquinone unit of the vitamin K alkoxide-epoxide is almost immersed
into membrane. Fig.5.A. shows a model of the hetero-dimeric form of VKC and VKOR with
the vitamin K from top view. Fig.5.B gives a schematic view of a hetero-dimeric form VKC
and VKOR with the intermediate structure of the Gla generation according to the Dowd
mechanism, from a top view. According to a recent model quantum calculation [25], the
chemical process for the generation of Gla in the vitamin K cycle favors aqueous
environment rather than lipid environment. It is consistent with prior biochemical
experiment that the deprotonation of the hydroquinone form of vitamin K by Lys218 and
subsequent initiation of the carboxylation reaction of VKC takes place near the lumen side
of the ER [30].
3.5 Prior biochemical mutation experiments
The hetero-dimer model concept can be tested by examining the growing body of mutational
data. An interesting case is the VKC hydrophobic residue, Trp157. According to our hetero-
dimer model, Trp157 is near Lys218 (VKC) at the surface of membrane in the lumen. With
this placement, Trp157 could be involved in the vitamin K catalysis rather than binding of
the substrate. This is consistent with W157R mutation experiment [40], in which the enzyme
activity of VKC is greatly reduced to 8%–10% of the wild type. However, a patient with the
mutation of W157R did not respond to vitamin K supplementation, which indicates,
according to Ref.[40] that the mutation does not affect the binding of VKD substrates [40].
On the other hand, His160, a possible candidate for the catalytic base for the deprotonation
of the hydroquinone form of vitamin K [30], may not be as near to oxy-3 as Lys218 since
the H160A mutation shows the activity of wild-type VKOR [30]. Another residue, Thr591,
putatively involved in both carboxylation and epoxidation activities [40], was predicted to
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be located in the lumen of the ER by both TM Prediction programs. Likewise, a L394R
mutation experiment on VKC suggests that Leu394 is involved in propeptide binding [41],
presumably at the lumen, and it thus consistent with our model. Recently, mutations in VKC
have been reported to be linked to pseudoxanthoma elasticum (PXE), an autosomal
recessive multi-system disorder with dystrophic mineralization of soft connective tissues
[42]. Patients with G537Y and G558R mutations in VKC showed PXE-like clinical features
[42]. Mutation experiments at these sites (predicted in the lumen in our model) in VKC
decreased the affinity of VKC for its substrates [42]. Similarly, mutations S300F and
V255M (also located in the lumen in the model) showed PXE-like clinical features. An
analysis of in vitro VKC enzyme assay experiments on these mutations suggests that these
mutations affect substrate binding [43]. The locations of the biochemically interesting sites
are shown in our hetero-dimer model in Fig.3.
3.6 Warfarin
Warfarin is a well-known anticoagulant, acting as a vitamin K antagonist [44,45]. It is
generally believed that warfarin inactivates VKOR by blocking the formation of the quinone
forms of vitamin K through non-competitive inhibition [24]. Although warfarin has been
widely used as a medication for preventing thrombosis, the molecular basis of the inhibition
mechanism of VKOR is still elusive. There are two enantiomeric forms, R- and S- warfarin
(see Supplemental Materials). S-warfarin is the biologically effective enantiomer [14]. We
geometry-optimized S-warfarin with the method/basis of B3lyp/6-31+g(d,p) similar to that
performed for vitamin K transients [25]. The putative binding motif of warfarin to VKOR is
thought, based on a body of data summarized in Ref.[46], to be at residues 138–140 (TYA),
which are positioned inside the membrane, three residues removed from the putative vitamin
K active site, cyteines and toward the center of the membrane in our model (See Fig. S3 in
Supporting Material). The displacement of the warfarin binding site away from the vitamin
K binding site (by at least one turn of the TM helix) is consistent with the observation that
warfarin is a non-competitive inhibitor [24]. The fully extended phenyl group of S-warfarin
may interact with the phenyl fragment of Tyr139 of VKOR in a stacking configuration [47].
It is interesting that there is structural evidence [47] that in the binding of S-warfarin to
P4502C9 (CYP2C9), the phenyl group of S-warfarin binds to Phe476, one of binding pocket
residues of CYP2C9, with a pi-pi stacking interaction. (see Supporting Material)
The mechanism for the reduction of the epoxide to the hydroquinone form of vitamin K in
the vitamin K cycle is not well understood [14]. A possibility for the reduction to the
hydroquinone could involve a flip-flop action of lipids in the ER membrane. The flip-flop of
lipids is thought to take place through either a pore-mediated process [48] or of enzyme
(flippase or floppase)-mediated process [49]. In this way, the naphthoquinone unit of the
quinone form of vitamin K could traverse a section of the pore by being coupled to the flip-
flop of lipids in the ER membrane and thereby the naphthoquinone unit could be reduced to
the hydroquinone form by reducing agents in or near the cytoplasm of the ER. After
reduction, the reduced form could cycle back via flip-flop to the lumen of the ER for the
initiation phase of the vitamin K cycle. The binding of S-warfarin to VKOR in the presence
of vitamin K could modify, i.e. reduce the rate of flip-flop of lipid membrane, ultimately
leading to the decrease of the amount of the vitamin K hydroquinone form.
An interesting recent development has been the discovery of warfarin-resistant VKOR
mutations in humans. Seven of these have been tabulated [50]: V29L, D36V, V45A, R58G,
V66M, L128R. Our co-localization hetero-dimer model would place all of these residues,
except V29 and L128, in the cytoplasm. A structural model for human VKOR, based on the
X-ray crystal structure of a bacterial analog of VKOR [51], however, would place all of
these residues in the ER lumen (See Supporting Material). This latter model has 4 VKOR
TM domains with the N terminus in the cytoplasm; our model has 3 VKOR TM domains
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with the N terminus located in the lumen. Both models predict essentially the same final two
TM domains (direction, sequence). Given that vitamin K supplementation is a standard
treatment for warfarin poisoning [52,53], that warfarin-resistant mutations exist [50], that
warfarin inhibition of the vitamin K cycle is non-competitive [24], and that lipid-protein
charge interactions can control the topology of TM domain [54,55], we are led to suggest
that the number of TM sequences in the ER membrane of residues 1–90 of VKOR may be
changed from 1 to 2; or some additional partial helix as seen in the X-ray structure of the
bacterial VKOR-like protein [34], so that additional TM-TM interactions are created which
modulate the warfarin binding site.
4. Conclusions
We have built a hetero-dimer model of VKC and VKOR in the presence of vitamin K based
on prior biochemical experiments, TM helix unit prediction methods, and quantum chemical
study. In our hetero-dimer of VKC and VKOR model, Lys218 and Trp157 are located near
the oxy-3 of vitamin K at the lumen side of the ER membrane. Two cysteines (Cys132 and
Cys135) of VKOR are located near oxy-2 inside the membrane. We propose a “5⊕3” TM
helix hetero-dimer model with a relatively open core for the mutual reactions of VKC and
VKOR. However, an extended 7⊕3 model for VKC/VKOR could also be considered while
still retaining the essential idea (limited diffusion of vitamin K and its intermediates) of the
hetero-dimer model. Obviously, the TM helices do not have to be as tightly packed as in our
“idealized” model, the helices could be at various angles to one another. The interaction of
VKC or VKOR with the lipid molecules in the membrane environment will affect the
dynamic arrangement of the TM helices, which will modulate the effective “pocket”
volume. Thus, it appears that the dynamical “pocket” of the helices for the minimalistic 5⊕3
hetero-dimer model, which co-localizes VKC and VKOR, can provide sufficient space for
the reactive glutamic acid side chains as well as water, vitamin K transients and/or warfarin.
Supplementary Material
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The vitamin K cycle as regulated by the two TM enzymes, vitamin K carboxylase (VKC)
and vitamin K epoxide reductase (VKOR).
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The topology of VKC and VKOR surmised from experiments and computer prediction.
Summarized are the prediction of TM helices units by experiments, TOPCONS and Philius
Transmembrane Prediction. A: summary of the topology of transmembrane helices of VKC.
B: summary of the topology of TM helices of VKOR.
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The model of hetero-dimeric form of VKC and VKOR. A possible relative position and
orientation of the naphthoquinone unit of vitamin K epoxide is shown. Loop size and
position are arbitrary. E represents Glu of a VKD, the substrate of VKC.
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The fully energy-optimized structures of the epoxide-alkoxide intermediate in the proposed
Dowd mechanism at the level of B3lyp/6–31+g(d,p). The intermediate is composed of three
different moieties, vitamin K epoxide, a water molecule and propionic acid, a model for
glutamic acid.
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A top view of a hetero-dimeric form of VKC and VKOR. A: Relative position and
orientation of the naphthoquinone unit of vitamin K epoxide. For clarity, loops are not
shown in this schematic picture. The diameter of the “pocket” is estimated to be 12Å and the
area 110Å2. B: Relative position and orientation of the intermediate from Fig.4 with a
respect to the hetero-dimer.
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